CA3190726A1 - Regimes posologiques longs et eleves d'antagonistes du vegf pour le traitement des angiogeneses oculaires - Google Patents

Regimes posologiques longs et eleves d'antagonistes du vegf pour le traitement des angiogeneses oculaires

Info

Publication number: CA3190726A1
Authority: CA; Canada
Prior art keywords: fusion protein; weeks; vegf receptor; receptor fusion; dose
Prior art date: 2022-03-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA3190726A

Other languages

English (en)

Inventor

Robert L. Vitti

Alyson J. BERLINER

Karen Chu

Friedrich Asmus

Sergio Casimiro DA SILVA LEAL

Thomas Eissing

Kay D. Rittenhouse

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Healthcare LLC

Regeneron Pharmaceuticals Inc

Original Assignee

Bayer Healthcare LLC

Regeneron Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2022-03-15

Filing date

2023-02-22

Publication date

2023-09-15

2023-02-22 Application filed by Bayer Healthcare LLC, Regeneron Pharmaceuticals Inc filed Critical Bayer Healthcare LLC

2023-03-14 Priority to JP2023039397A priority Critical patent/JP2023135645A/ja

2023-03-14 Priority to AU2023234355A priority patent/AU2023234355A1/en

2023-03-14 Priority to US18/121,490 priority patent/US20230295266A1/en

2023-03-14 Priority to PCT/US2023/015223 priority patent/WO2023177689A1/fr

2023-03-14 Priority to CN202380025696.0A priority patent/CN119365206A/zh

2023-03-14 Priority to CA3254467A priority patent/CA3254467A1/fr

2023-03-14 Priority to IL315347A priority patent/IL315347A/en

2023-03-15 Priority to KR1020230034203A priority patent/KR20230135012A/ko

2023-03-15 Priority to TW112109574A priority patent/TW202400215A/zh

2023-03-15 Priority to AU2023201635A priority patent/AU2023201635A1/en

2023-03-15 Priority to EP23162091.5A priority patent/EP4245313A1/fr

2023-09-15 Publication of CA3190726A1 publication Critical patent/CA3190726A1/fr

2024-09-10 Priority to CL2024002718A priority patent/CL2024002718A1/es

2024-09-11 Priority to MX2024011132A priority patent/MX2024011132A/es

2025-06-17 Priority to CL2025001801A priority patent/CL2025001801A1/es

Status Pending legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 339
230000002491 angiogenic effect Effects 0.000 title claims abstract description 24
208000030533 eye disease Diseases 0.000 title claims abstract description 24
239000005557 antagonist Substances 0.000 title description 51
101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
101150030763 Vegfa gene Proteins 0.000 title 1
108010081667 aflibercept Proteins 0.000 claims abstract description 549
229960002833 aflibercept Drugs 0.000 claims abstract description 540
108091008605 VEGF receptors Proteins 0.000 claims description 709
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 709
108020001507 fusion proteins Proteins 0.000 claims description 702
102000037865 fusion proteins Human genes 0.000 claims description 702
238000000034 method Methods 0.000 claims description 224
230000000977 initiatory effect Effects 0.000 claims description 168
239000000203 mixture Substances 0.000 claims description 133
238000002347 injection Methods 0.000 claims description 132
239000007924 injection Substances 0.000 claims description 132
206010012688 Diabetic retinal oedema Diseases 0.000 claims description 129
201000011190 diabetic macular edema Diseases 0.000 claims description 129
238000009472 formulation Methods 0.000 claims description 129
239000000872 buffer Substances 0.000 claims description 118
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 115
229930006000 Sucrose Natural products 0.000 claims description 115
239000005720 sucrose Substances 0.000 claims description 115
206010012689 Diabetic retinopathy Diseases 0.000 claims description 102
238000012423 maintenance Methods 0.000 claims description 102
230000006872 improvement Effects 0.000 claims description 88
230000002207 retinal effect Effects 0.000 claims description 87
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 84
229920001213 Polysorbate 20 Polymers 0.000 claims description 83
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 83
229940068977 polysorbate 20 Drugs 0.000 claims description 83
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 81
230000008859 change Effects 0.000 claims description 77
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 62
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 62
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 51
239000008194 pharmaceutical composition Substances 0.000 claims description 50
239000012530 fluid Substances 0.000 claims description 48
229930064664 L-arginine Natural products 0.000 claims description 43
235000014852 L-arginine Nutrition 0.000 claims description 43
206010038848 Retinal detachment Diseases 0.000 claims description 29
108700036276 KH902 fusion Proteins 0.000 claims description 28
229910019142 PO4 Inorganic materials 0.000 claims description 28
229950005748 conbercept Drugs 0.000 claims description 28
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 28
239000010452 phosphate Substances 0.000 claims description 28
150000001413 amino acids Chemical class 0.000 claims description 27
210000002301 subretinal fluid Anatomy 0.000 claims description 27
210000001525 retina Anatomy 0.000 claims description 26
238000012014 optical coherence tomography Methods 0.000 claims description 24
235000001014 amino acid Nutrition 0.000 claims description 23
239000013628 high molecular weight specie Substances 0.000 claims description 22
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 20
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 19
229920001184 polypeptide Polymers 0.000 claims description 19
102000004196 processed proteins & peptides Human genes 0.000 claims description 19
108090000765 processed proteins & peptides Proteins 0.000 claims description 19
230000004304 visual acuity Effects 0.000 claims description 18
101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 17
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 17
230000001965 increasing effect Effects 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 15
239000004094 surface-active agent Substances 0.000 claims description 15
239000004475 Arginine Substances 0.000 claims description 14
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
235000009697 arginine Nutrition 0.000 claims description 14
238000013534 fluorescein angiography Methods 0.000 claims description 14
238000011269 treatment regimen Methods 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 13
235000000346 sugar Nutrition 0.000 claims description 13
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
238000000746 purification Methods 0.000 claims description 12
230000009467 reduction Effects 0.000 claims description 12
208000001344 Macular Edema Diseases 0.000 claims description 11
206010025415 Macular oedema Diseases 0.000 claims description 11
201000010230 macular retinal edema Diseases 0.000 claims description 11
238000003860 storage Methods 0.000 claims description 11
230000003247 decreasing effect Effects 0.000 claims description 8
206010061218 Inflammation Diseases 0.000 claims description 7
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
230000004054 inflammatory process Effects 0.000 claims description 7
239000013011 aqueous formulation Substances 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
150000007523 nucleic acids Chemical group 0.000 claims description 6
239000004033 plastic Substances 0.000 claims description 6
229920003023 plastic Polymers 0.000 claims description 6
239000001488 sodium phosphate Substances 0.000 claims description 6
229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 6
230000002792 vascular Effects 0.000 claims description 6
230000000007 visual effect Effects 0.000 claims description 6
206010029113 Neovascularisation Diseases 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
230000004410 intraocular pressure Effects 0.000 claims description 5
230000002085 persistent effect Effects 0.000 claims description 5
229940071643 prefilled syringe Drugs 0.000 claims description 5
230000002829 reductive effect Effects 0.000 claims description 5
238000004904 shortening Methods 0.000 claims description 5
230000003595 spectral effect Effects 0.000 claims description 5
230000004382 visual function Effects 0.000 claims description 5
208000032843 Hemorrhage Diseases 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 4
208000026935 allergic disease Diseases 0.000 claims description 4
238000001035 drying Methods 0.000 claims description 4
239000011521 glass Substances 0.000 claims description 4
230000009610 hypersensitivity Effects 0.000 claims description 4
239000002736 nonionic surfactant Substances 0.000 claims description 4
238000004806 packaging method and process Methods 0.000 claims description 4
229920005862 polyol Polymers 0.000 claims description 4
150000003077 polyols Chemical class 0.000 claims description 4
238000002203 pretreatment Methods 0.000 claims description 4
230000001681 protective effect Effects 0.000 claims description 4
230000003442 weekly effect Effects 0.000 claims description 4
108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
102000005962 receptors Human genes 0.000 claims description 3
108020003175 receptors Proteins 0.000 claims description 3
206010002091 Anaesthesia Diseases 0.000 claims description 2
208000002177 Cataract Diseases 0.000 claims description 2
206010010719 Conjunctival haemorrhage Diseases 0.000 claims description 2
206010011010 Corneal epithelium defect Diseases 0.000 claims description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
241001602876 Nata Species 0.000 claims description 2
208000034699 Vitreous floaters Diseases 0.000 claims description 2
230000037005 anaesthesia Effects 0.000 claims description 2
238000004140 cleaning Methods 0.000 claims description 2
230000000881 depressing effect Effects 0.000 claims description 2
238000002845 discoloration Methods 0.000 claims description 2
210000000744 eyelid Anatomy 0.000 claims description 2
238000011534 incubation Methods 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
230000003641 microbiacidal effect Effects 0.000 claims description 2
229940124561 microbicide Drugs 0.000 claims description 2
239000002855 microbicide agent Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
230000001737 promoting effect Effects 0.000 claims description 2
238000010079 rubber tapping Methods 0.000 claims description 2
238000004659 sterilization and disinfection Methods 0.000 claims description 2
230000000699 topical effect Effects 0.000 claims description 2
208000000318 vitreous detachment Diseases 0.000 claims description 2
238000012544 monitoring process Methods 0.000 claims 1
229960002885 histidine Drugs 0.000 description 69
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 56
229940090044 injection Drugs 0.000 description 47
239000003638 chemical reducing agent Substances 0.000 description 33
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 29
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 29
229940068968 polysorbate 80 Drugs 0.000 description 29
229920000053 polysorbate 80 Polymers 0.000 description 29
239000011780 sodium chloride Substances 0.000 description 28
-1 for example Chemical compound 0.000 description 25
229920001219 Polysorbate 40 Polymers 0.000 description 24
239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 24
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 24
229940101027 polysorbate 40 Drugs 0.000 description 24
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 24
229940024606 amino acid Drugs 0.000 description 19
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 18
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
229960003080 taurine Drugs 0.000 description 12
229960003121 arginine Drugs 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
235000018102 proteins Nutrition 0.000 description 10
239000003017 thermal stabilizer Substances 0.000 description 10
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 9
206010064930 age-related macular degeneration Diseases 0.000 description 9
229960002429 proline Drugs 0.000 description 9
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 9
238000011002 quantification Methods 0.000 description 9
208000004644 retinal vein occlusion Diseases 0.000 description 9
KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 8
229960003589 arginine hydrochloride Drugs 0.000 description 8
229940051306 eylea Drugs 0.000 description 8
239000002525 vasculotropin inhibitor Substances 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
208000000208 Wet Macular Degeneration Diseases 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
206010012601 diabetes mellitus Diseases 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000005590 Choroidal Neovascularization Diseases 0.000 description 6
206010060823 Choroidal neovascularisation Diseases 0.000 description 6
108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 6
201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 6
229940126534 drug product Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000008030 elimination Effects 0.000 description 6
238000003379 elimination reaction Methods 0.000 description 6
239000000825 pharmaceutical preparation Substances 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
208000010412 Glaucoma Diseases 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
208000031471 Macular fibrosis Diseases 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
238000001914 filtration Methods 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
239000000710 homodimer Substances 0.000 description 4
230000003902 lesion Effects 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000005070 sampling Methods 0.000 description 4
239000000600 sorbitol Substances 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
201000004569 Blindness Diseases 0.000 description 3
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
206010065630 Iris neovascularisation Diseases 0.000 description 3
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
229930182821 L-proline Natural products 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
206010025421 Macule Diseases 0.000 description 3
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
230000002411 adverse Effects 0.000 description 3
229960000106 biosimilars Drugs 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000011068 loading method Methods 0.000 description 3
235000018977 lysine Nutrition 0.000 description 3
235000013923 monosodium glutamate Nutrition 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
229940044519 poloxamer 188 Drugs 0.000 description 3
229920001993 poloxamer 188 Polymers 0.000 description 3
229940050929 polyethylene glycol 3350 Drugs 0.000 description 3
230000004845 protein aggregation Effects 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
229940073490 sodium glutamate Drugs 0.000 description 3
WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
230000004393 visual impairment Effects 0.000 description 3
QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 2
WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
206010008190 Cerebrovascular accident Diseases 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
208000001351 Epiretinal Membrane Diseases 0.000 description 2
208000001860 Eye Infections Diseases 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
208000007135 Retinal Neovascularization Diseases 0.000 description 2
208000002367 Retinal Perforations Diseases 0.000 description 2
206010038934 Retinopathy proliferative Diseases 0.000 description 2
206010039705 Scleritis Diseases 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
206010047571 Visual impairment Diseases 0.000 description 2
208000034698 Vitreous haemorrhage Diseases 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
201000004982 autoimmune uveitis Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
208000010217 blepharitis Diseases 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
201000005667 central retinal vein occlusion Diseases 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
206010011005 corneal dystrophy Diseases 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
230000003205 diastolic effect Effects 0.000 description 2
230000009266 disease activity Effects 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
229960005150 glycerol Drugs 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
208000029233 macular holes Diseases 0.000 description 2
230000003818 metabolic dysfunction Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
201000009015 preretinal fibrosis Diseases 0.000 description 2
230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
229960003876 ranibizumab Drugs 0.000 description 2
230000004264 retinal detachment Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229960002117 triamcinolone acetonide Drugs 0.000 description 2
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
208000029257 vision disease Diseases 0.000 description 2
102100034608 Angiopoietin-2 Human genes 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010055665 Corneal neovascularisation Diseases 0.000 description 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
229930028154 D-arginine Natural products 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108010041308 Endothelial Growth Factors Proteins 0.000 description 1
102100039250 Essential MCU regulator, mitochondrial Human genes 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
101150048336 Flt1 gene Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
101000813097 Homo sapiens Essential MCU regulator, mitochondrial Proteins 0.000 description 1
101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
101150088608 Kdr gene Proteins 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001111421 Pannus Species 0.000 description 1
201000010183 Papilledema Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
201000002154 Pterygium Diseases 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038886 Retinal oedema Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 1
244000126002 Ziziphus vulgaris Species 0.000 description 1
108010043116 abicipar pegol Proteins 0.000 description 1
229950008281 abicipar pegol Drugs 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000003926 acrylamides Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940027545 aflibercept injection Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000002137 anti-vascular effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
201000007917 background diabetic retinopathy Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
229950000025 brolucizumab Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
HISOCSRUFLPKDE-KLXQUTNESA-N cmt-2 Chemical compound C1=CC=C2[C@](O)(C)C3CC4C(N(C)C)C(O)=C(C#N)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O HISOCSRUFLPKDE-KLXQUTNESA-N 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
201000000159 corneal neovascularization Diseases 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229960002806 daclizumab Drugs 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000004438 eyesight Effects 0.000 description 1
229940116862 faricimab Drugs 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
210000003811 finger Anatomy 0.000 description 1
229940085942 formulation r Drugs 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
229960003446 histidine monohydrochloride Drugs 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229960003407 pegaptanib Drugs 0.000 description 1
229940005014 pegaptanib sodium Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
201000011195 retinal edema Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000013598 vector Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
230000004412 visual outcomes Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CA3190726A 2022-03-15 2023-02-22 Regimes posologiques longs et eleves d'antagonistes du vegf pour le traitement des angiogeneses oculaires Pending CA3190726A1 (fr)

Priority Applications (14)

Application Number	Priority Date	Filing Date	Title
JP2023039397A JP2023135645A (ja)	2022-03-15	2023-03-14	血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン
AU2023234355A AU2023234355A1 (en)	2022-03-15	2023-03-14	Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
US18/121,490 US20230295266A1 (en)	2022-03-15	2023-03-14	Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
PCT/US2023/015223 WO2023177689A1 (fr)	2022-03-15	2023-03-14	Régimes d'antagoniste de vegf à dose élevée et étendu pour le traitement de troubles oculaires angiogéniques
CN202380025696.0A CN119365206A (zh)	2022-03-15	2023-03-14	用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
CA3254467A CA3254467A1 (fr)	2022-03-15	2023-03-14	Régimes d'antagoniste de vegf à dose élevée et étendu pour le traitement de troubles oculaires angiogéniques
IL315347A IL315347A (en)	2022-03-15	2023-03-14	Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
KR1020230034203A KR20230135012A (ko)	2022-03-15	2023-03-15	혈관형성 눈 장애의 치료를 위한 연장된 고 용량 vegf 길항제 용법
TW112109574A TW202400215A (zh)	2022-03-15	2023-03-15	用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案
AU2023201635A AU2023201635A1 (en)	2022-03-15	2023-03-15	Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
EP23162091.5A EP4245313A1 (fr)	2022-03-15	2023-03-15	Régimes d'antagonistes de vegf étendus et à dose élevée pour le traitement de troubles oculaires angiogéniques
CL2024002718A CL2024002718A1 (es)	2022-03-15	2024-09-10	Regímenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogénicos.
MX2024011132A MX2024011132A (es)	2022-03-15	2024-09-11	Regimenes extendidos, con dosis altas de antagonistas de vegf para el tratamiento de trastornos oculares angiogenicos
CL2025001801A CL2025001801A1 (es)	2022-03-15	2025-06-17	Uso de aflibercept para tratar o prevenir retinopatía diabética y/o el edema macular diabético.

Applications Claiming Priority (16)

Application Number	Priority Date	Filing Date
US202263319865P	2022-03-15	2022-03-15
US63/319,865		2022-03-15
US202263404511P	2022-09-07	2022-09-07
US63/404,511		2022-09-07
US202263404889P	2022-09-08	2022-09-08
US63/404,889		2022-09-08
US202263411589P	2022-09-29	2022-09-29
US63/411,589		2022-09-29
US202263412158P	2022-09-30	2022-09-30
US63/412,158		2022-09-30
US202263421296P	2022-11-01	2022-11-01
US63/421,296		2022-11-01
US202263434918P	2022-12-22	2022-12-22
US63/434,918		2022-12-22
US202363444470P	2023-02-09	2023-02-09
US63/444,470		2023-02-09

Publications (1)

Publication Number	Publication Date
CA3190726A1 true CA3190726A1 (fr)	2023-09-15

Family

ID=87975465

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA3190726A Pending CA3190726A1 (fr)	2022-03-15	2023-02-22	Regimes posologiques longs et eleves d'antagonistes du vegf pour le traitement des angiogeneses oculaires

Country Status (1)

Country	Link
CA (1)	CA3190726A1 (fr)

2023
- 2023-02-22 CA CA3190726A patent/CA3190726A1/fr active Pending

Publication	Publication Date	Title
US11071780B2 (en)	2021-07-27	Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
EP4245313A1 (fr)	2023-09-20	Régimes d'antagonistes de vegf étendus et à dose élevée pour le traitement de troubles oculaires angiogéniques
AU2022275786B2 (en)	2025-06-05	Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
EP4245312A1 (fr)	2023-09-20	Régimes d'antagonistes de vegf étendus et à dose élevée pour le traitement de troubles oculaires angiogéniques
CA3190726A1 (fr)	2023-09-15	Regimes posologiques longs et eleves d'antagonistes du vegf pour le traitement des angiogeneses oculaires
EP4480491A1 (fr)	2024-12-25	Régimes d'antagonistes de vegf étendus et à dose élevée pour le traitement de troubles oculaires angiogéniques
HK40099475A (en)	2024-04-19	Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
HK40099476A (en)	2024-04-19	Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CA3190733A1 (fr)	2023-09-15	Regimes posologiques longs et eleves d'antagonistes du vegf pour le traitement des angiogeneses oculaires
HK40119109A (en)	2025-07-11	Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Legal Events

Date	Code	Title	Description
2023-11-16	EEER	Examination request	Effective date: 20231106
2023-11-21	EEER	Examination request	Effective date: 20231106
2024-03-26	EEER	Examination request	Effective date: 20231106
2024-04-08	EEER	Examination request	Effective date: 20231106
2024-05-01	EEER	Examination request	Effective date: 20231106